scholarly article | Q13442814 |
P819 | ADS bibcode | 2018NatCo...9.4070R |
P356 | DOI | 10.1038/S41467-018-06602-6 |
P932 | PMC publication ID | 6172284 |
P698 | PubMed publication ID | 30287819 |
P50 | author | Ronen Alon | Q56931491 |
Margherita Morpurgo | Q56998938 | ||
Roberto Ronca | Q58660977 | ||
Giampietro Viola | Q66360924 | ||
Elena Porcù | Q84112093 | ||
Fatlum Rruga | Q92046448 | ||
P2093 | author name string | Giuseppe Basso | |
Elisabetta Casarin | |||
Nicola Realdon | |||
Federica Maccarinelli | |||
Francesco Roncato | |||
P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
Three-dimensional structures of avidin and the avidin-biotin complex | Q24562803 | ||
Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 | ||
Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry | Q28544658 | ||
Clathrin-independent endocytosis of ubiquitinated cargos | Q33864329 | ||
Methyl 4-mercaptobutyrimidate as a cleavable crosslinking reagent and its application to the Escherichia coli 30S ribosome | Q34213591 | ||
Detection of a fluorescent-labeled avidin-nucleic acid nanoassembly by confocal laser endomicroscopy in the microvasculature of chronically inflamed intestinal mucosa | Q34960433 | ||
Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. | Q35004254 | ||
Activation of KRAS promotes the mesenchymal features of basal-type breast cancer | Q35040663 | ||
Liposome-based approaches to overcome anticancer drug resistance | Q35595419 | ||
A New ELISA Using the ANANAS Technology Showing High Sensitivity to diagnose the Bovine Rhinotracheitis from Individual Sera to Pooled Milk | Q35892892 | ||
Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer | Q36106734 | ||
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer | Q36145430 | ||
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. | Q36832116 | ||
A Micelle Self-Assembled from Doxorubicin-Arabinoxylan Conjugates with pH-Cleavable Bond for Synergistic Antitumor Therapy | Q37608021 | ||
Antibody-drug conjugates: current status and future directions | Q38163255 | ||
Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration | Q38998238 | ||
The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis | Q39014347 | ||
Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies | Q39253031 | ||
In vivo fate of avidin-nucleic acid nanoassemblies as multifunctional diagnostic tools. | Q39297207 | ||
Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. | Q39361715 | ||
Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth | Q39446636 | ||
DNMT3a plays a role in switches between doxorubicin-induced senescence and apoptosis of colorectal cancer cells | Q39703300 | ||
Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity | Q40302861 | ||
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys | Q40395390 | ||
Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier | Q41078784 | ||
Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model. | Q41183225 | ||
Optimized avidin nucleic acid nanoassemblies by a tailored PEGylation strategy and their application as molecular amplifiers in detection. | Q43043093 | ||
New hydrazone derivatives of adriamycin and their immunoconjugates--a correlation between acid stability and cytotoxicity | Q43863877 | ||
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. | Q44480735 | ||
DNA condensation by high-affinity interaction with avidin. | Q45073809 | ||
Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. | Q50896680 | ||
Antibody–Drug Conjugates for Tumor Targeting—Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins | Q57839848 | ||
Preparation and some properties of maleimido acids and maleoyl derivatives of peptides | Q67248802 | ||
A method for the estimation of polyethylene glycol in plasma protein fractions | Q71387757 | ||
(6-Maleimidocaproyl)hydrazone of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin | Q71609322 | ||
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates | Q72822953 | ||
A SPECTROPHOTOMETRIC ASSAY FOR AVIDIN AND BIOTIN BASED ON BINDING OF DYES BY AVIDIN | Q78535145 | ||
Characterization of multifunctional nanosystems based on the avidin-nucleic acid interaction as signal enhancers in immuno-detection | Q83636317 | ||
Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity | Q89428061 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P4510 | describes a project that uses | ImageJ | Q1659584 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | nanotechnology | Q11468 |
P304 | page(s) | 4070 | |
P577 | publication date | 2018-10-04 | |
P1433 | published in | Nature Communications | Q573880 |
P1476 | title | Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies | |
P478 | volume | 9 |
Q91891550 | Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems |
Q99579060 | Biointerface engineering nanoplatforms for cancer-targeted drug delivery |
Q64944222 | Cryptotanshinone Suppresses Non-Small Cell Lung Cancer via microRNA-146a-5p/EGFR Axis. |
Q64945320 | Nanoparticle Activation Methods in Cancer Treatment. |
Q94562089 | Selective delivery of T22-PE24-H6 to CXCR4+ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model |
Search more.